Antiviral therapy: quo vadis?
2010; Future Science Ltd; Volume: 2; Issue: 7 Linguagem: Inglês
10.4155/fmc.10.22
ISSN1756-8927
Autores Tópico(s)Hepatitis B Virus Studies
ResumoFuture Medicinal ChemistryVol. 2, No. 7 EditorialFree AccessAntiviral therapy: quo vadis?Erik De ClercqErik De ClercqRega Institute for Medical Research, K.U.Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Published Online:12 Jul 2010https://doi.org/10.4155/fmc.10.22AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail As of 2008, that is, 25 years after the discovery of HIV as the causative agent of AIDS [1–3], exactly 25 compounds had been officially approved for the treatment of AIDS [4,5].Then, in 2009, we commemorated what could be considered the 50th anniversary of the start of antiviral chemotherapy – that is following the synthesis 50 years ago of 5-iodo-2´-deoxyuridine (IDU) [6], which would later become the first antiviral drug to be licensed for clinical use [7]. IDU is still used in eye drops or as an ointment for the topical treatment of herpetic eye infections.This year, 2010, marks another anniversary: 25 years ago since azidothymidine (AZT; zidovudine, Retrovir®) was first described as an antiretroviral agent [8]. Then, in 1987 it became the first drug to be specifically approved for the treatment of AIDS [9].Now, 50 years after the first antiviral drug was described, there are approximately 50 antiviral compounds (Table 1) approved by the US FDA. Half of these compounds are for the treatment of HIV infections; the other half are for the treatment of herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus, hepatitis B virus (HBV) and hepatitis C virus (HCV) and influenza A virus infections.HIV infectionsFor the treatment of HIV infections, we now have 25 approved anti-HIV drugs [4,5]. The explosion of anti-HIV drugs could hardly be foreseen when AZT was reported in 1985 [8]. AZT was far from ideal, but it launched the search for newer compounds with increased potency and safety, thereby divulging new targets and options for therapy. The result of these endeavors was phenomenal: 25 compounds within 25 years: nucleoside reverse transcriptase inhibitors (NRTIs): zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, emtricitabine (a brief history on the discovery of stavudine [10] and NRTIs in general can be found elsewhere [11]); one nucleotide reverse transcriptase inhibitor (NtRTI): tenofovir disoproxil fumarate (TDF, [12]); four non-nucleoside reverse transcriptase inhibitors (NNRTIs): nevirapine, delavirdine, efavirenz and etravirine (recent review on NNRTIs can be found elsewhere [13]); ten protease inhibitors (PIs): saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir; one fusion inhibitor: enfuvirtide; one coreceptor inhibitor: maraviroc; and one integrase inhibitor (INI): raltegravir (the significance of integrase strand-transfer inhibitors in antiretroviral therapy is discussed elsewhere [14]).The treatment of HIV infections has brought about a barely explored antiviral strategy, that is combination therapy, particularly between an NRTI, an NtRTI and either a PI or a NNRTI. A fixed-dose triple drug combination is Atripla®, a single pill (to be taken daily) combining one NRTI, one NtRTI, one NNRTI and another fixed-dose combination, the quadruple combination in a single pill, such as one containing the NtRTI TDF, the NRTI emtricibatine, the INI elvitegravir and a booster, cobicistat, is forthcoming.HBV infectionsHepatitis B virus replicates through a similar reverse transcription step (catalysed by a similar RNA-dependent DNA polymerase) as HIV. In addition HBV is transmitted by the same routes as HIV, that is, parenterally, sexually, or perinatally (from mother-to-child). Of essence, TDF (Viread®) [12,15,16] has recently been approved for the treatment of HBV infections, thus bringing the total number of licensed anti-HBV drugs, besides interferon, to five (lamivudine, adefovir dipivoxil, entecavir, telbivudine and TDF). While drug combination is the 'standard' care for the treatment of HIV infections, this procedure has not (so far) received wide acceptance for the treatment of HBV infections. TDF (at a dose of 300 mg/day) has proven more efficacious than adefovir dipivoxil (at a dose of 10 mg/day) in the treatment of chronic hepatitis B [17].HCV infectionsIn the case of HCV infections, the prospects of eradicating the virus from its reservoirs should, in theory, be better than for HBV or HIV infections, given that HCV, as an RNA virus, does not have a proviral DNA hideaway (as do retroviruses, such as HIV, or hepadnaviruses, such as HBV). Standard care for chronic hepatitis C currently exists of (pegylated) interferon combined with ribavirin [18], efforts are currently underway in the pharmaceutical industry [18], aimed at developing HCV inhibitors that are targeted at HCV-specific enzymes such as the viral protease and viral RNA-dependent RNA polymerase [19].A new antiviral strategy specifically intended to treat HCV infections is based upon cyclophilin inhibitors [20], including the nonimmunosuppressive cyclosporine A analogue, Debio 025 (alisporivir), which is currently in Phase IIb development, and which could become part of the future standard care for hepatitis C.Influenza virus infectionsRecent progress in the chemotherapy or prophylaxis of influenza virus infections has not been as impressive as for HIV, HBV or HCV infections, despite the continuous reminders of the importance of seasonal influenza A H3N2 and H1N1 epidemics, the avian influenza H5N1 threat and the recent swine influenza A H1N1 outbreak ('pandemic'). Neuraminidase inhibitors oseltamivir (Tamiflu®) and zanamivir (Relenza®) have remained the 'standard' antiviral drugs for the treatment of influenza virus infections [21,22].A novel swine-origin influenza A virus S-OIV was identified as the cause of outbreaks of febrile respiratory infection ranging from self-limited to severe illness [23]. It is likely that the number of confirmed cases is an underestimation. A triple-reassortant strain was identified in specimens from patients with infection with triple-reassortant swine influenza viruses before the current epidemic of human infection with S-OIV [24].It is hard to predict how S-OIV, avian influenza and/or other influenza A epidemics will evolve in the near, let alone, distant future. Continuous vigilance is warranted, and, as a standard precaution, neuraminidase inhibitors (e.g., oseltamivir) ought to be considered to block the virus infection and prevent its spread.Dengue virusThe WHO has estimated that 40–100 million people are infected each year with Dengue viruses (any of the four serotypes), in the worst cases resulting in dengue hemorrhagic fever and dengue shock syndrome. In the absence of any vaccine, the rapid development of chemotherapeutics is urgently needed, but despite this urgency, and the multitude of approaches that are being considered [25], we are still eagerly waiting for a druggable product to treat Dengue virus infections.Future perspectiveThere are at present approximately circa 50 antiviral drugs available, half of them for the treatment of HIV infections. Combination of anti-HIV drugs has made AIDS a treatable chronic disease. While for chronic hepatitis B, treatment is generally based on monotherapy, the treatment of hepatitis C will again be driven by multiple drug combinations, initially containing ribavirin and (pegylated) interferon. Treatment of influenza virus remains governed by neuraminidase inhibitors, and for the treatment of hemorrhagic fever virus infections, such as Dengue, antiviral drug strategies are being developed. Where the viral disease cannot be controlled by vaccination, such as AIDS, the prophylactic use of anti-HIV agents could have a profound global impact on the spread of the disease.Table 1. Antiviral drugs approved by the US FDA.Registered brand nameGeneric nameManufacturerAnti-HIV compoundsNucleoside reverse transcriptase inhibitorsRetrovir®ZidovudineGlaxoSmithKlineVidex®, Videx® ECDidanosineBristol-Myers SquibbHivid®ZalcitabineRocheZerit®StavudineBristol-Myers SquibbEpivir®, Zeffix®LamivudineGlaxoSmithKlineZiagen®AbacavirGlaxoSmithKlineEmtriva®Emtricitabine ([-]FTC)Gilead SciencesCombivir®Lamivudine and ZidovudineGlaxoSmithKlineTrizivir®Abacavir, lamivudine and zidovudineGlaxoSmithKlineEpzicom®Abacavir and lamivudineGlaxoSmithKlineNucleotide reverse transcriptase inhibitorsViread®Tenofovir disoproxil fumarateGilead SciencesTruvada®Tenofovir disoproxil fumarate and emtricitabineGilead SciencesAtripla®Tenofovir disoproxil fumarate, emtricitabine and efavirenzGilead Sciences and Bristol-Myers SquibbNon-nucleoside reverse transcriptase inhibitorsViramune®NevirapineBoehringer IngelheimRescriptor®DelavirdinePfizerSustiva®, Stocrin®EfavirenzBristol-Myers SquibbIntelence®EtravirineTibotecProtease inhibitorsFortovase®SaquinavirRocheNorvir®RitonavirAbbottCrixivan®IndinavirMerckViracept®NelfinavirPfizerAgenerase®, Prozei®AmprenavirGlaxoSmithKlineKaletra®Lopinavir and ritonavirAbbottReyataz®AtazanavirBristol-Myers SquibbLexiva®FosamprenavirGlaxoSmithKlineAptivus®TipranavirBoehringer IngelheimPrezista®DarunavirTibotecViral entry inhibitorsCo-receptor inhibitorsSelzentry®, Celsentri®MaravirocPfizerFusion inhibitorsFuzeon®EnfuvirtideRocheIntegrase inhibitorsIsentress®RaltegravirMerckAnti-hepatitis B virus compoundsEpivir®, Zeffix®LamivudineGlaxoSmithKlineHepsera®Adefovir dipivoxilGilead SciencesBaraclude®EntecavirBristol-Myers SquibbTyzeka®, Sebivo®TelbivudineIdenix PharmaceuticalsViread®Tenofovir disoproxil fumarateGilead SciencesIntron A®IFN-α-2bSchering-PloughPegasys®Pegylated IFN-α-2aRocheAnti-herpesvirus compoundsHerpes simplex virus and varicella-zoster virus inhibitorsZovirax®AcyclovirGlaxoSmithKlineZelitrex®, Valtrex®ValaciclovirGlaxoSmithKlineDenavir®, Vectavir®PenciclovirNovartisFamvir®FamciclovirNovartisHerpid®, Stoxil®, Idoxene®, Virudox®IdoxuridineYale UniversityViroptic®TrifluridineKing PharmaceuticalsZostex®, Brivirac®, Zerpex®Brivudin†Berlin Chemie/MenariniCytomegalovirus inhibitorsCymevene®, Cytovene®GanciclovirRocheValcyte®ValganciclovirRocheFoscavir®FoscarnetAstra ZenecaVistide®CidofovirPfizerVitravene®FomivirsenNovartisAnti-influenzavirus compoundsSymmetrel®, Mantadix®, Amantan®AmantadineEndo PharmaceuticalsFlumadine®RimantadineForest LaboratoriesRelenza®ZanamivirGlaxoSmithKlineTamiflu®OseltamivirRocheVirazole®, Virazid®, Viramid®RibavirinValeant PharmaceuticalsAnti-hepatitis C virus compoundsRebetol®RibavirinSchering-PloughCopegus®RibavirinRochePegasys®Pegylated IFN-α-2aRocheRoferon A®IFN-α-2aRocheIntron A®IFN-α-2bSchering-PloughPEG-Intron®Pegylated IFN-α-2bSchering-PloughRebetron®IFN-α-2b plus ribavirinSchering-Plough†Not formally approved by the US FDA.AcknowledgementsThe author would like to thank Mrs Christiane Callebaut for her proficient editorial assistance.Financial & competing interests disclosureThe author is co-discoverer of tenofovir. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interestBibliography1 Popovic M, Sarin PS, Rubert-Gurroff M et al. Isolation and transmission of human retrovirus (human T-cell leukemia virus). Science219,856–859 (1983).▪▪ Represents start of the HIV era.Crossref, Medline, CAS, Google Scholar2 Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science220,868–871 (1983).▪▪ Start of the HIV era, as recognized in 2008 by the award of the Nobel Prize in Physiology or Medicine to Françoise Barré-Sinoussi and Luc Montagnier.Crossref, Medline, CAS, Google Scholar3 Vahlne A. A historical reflection on the discovery of human retroviruses. Retrovirology6,40 (2009).▪▪ Discusses how HIV-1 was discovered and established as the cause of AIDS.Crossref, Medline, Google Scholar4 De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents33,307–320 (2009).Crossref, Medline, CAS, Google Scholar5 De Clercq E. The history of antiretrovirals: key discoveries over the past 25 years. Rev. Med. Virol.19,287–299 (2009).Crossref, Medline, CAS, Google Scholar6 Prusoff WH. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim. Biophys. Acta32,295–296 (1959).Crossref, Medline, CAS, Google Scholar7 De Clercq E. Looking back in 2009 at the dawning of antiviral therapy now 50 years ago: an historical perspective. Adv. Virus Res.73,1–53 (2009).▪ Overview of antiviral research during the past 50 years.Crossref, Medline, CAS, Google Scholar8 Mitsuya H, Weinhold KJ, Furman PA et al. 3´-azido-3´-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl Acad. Sci. USA82,7096–7100 (1985).Crossref, Medline, CAS, Google Scholar9 Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res.85,1–18 (2010).▪▪ How a laboratory observation ignited the current treatment policy for HIV-1/AIDS worldwide.Crossref, Medline, CAS, Google Scholar10 Martin JC, Hitchcock MJM, De Clercq E, Prusoff WH. Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides. Antiviral Res.85,34–38 (2010).Crossref, Medline, CAS, Google Scholar11 Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res.85,39–58 (2010).Crossref, Medline, CAS, Google Scholar12 De Clercq E. Tenofovir disoproxil fumarate (TDF): discovery and clinical development. In: Antiviral Drugs: Biology, Chemistry, Clinic, Kazmierski WM (Ed.). John Wiley & Sons, Inc (2010) (In Press).Google Scholar13 de Béthune M-P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). Antiviral Res.85,75–90 (2010).Crossref, Medline, CAS, Google Scholar14 McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res.85,101–118 (2010).Crossref, Medline, CAS, Google Scholar15 Perry CM, Simpson D. Tenofovir disoproxil fumarate in chronic hepatitis B. Drugs69,2245–2256 (2009).Crossref, Medline, CAS, Google Scholar16 Reynaud L, Carleo MA, Talamo M, Borgia G. Tenofovir and its potential in the treatment of hepatitis B virus. Ther. Clin. Risk Manag.5,177–185 (2009).Medline, CAS, Google Scholar17 Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med.359,2442–2455 (2008).Crossref, Medline, CAS, Google Scholar18 Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim H, Houghton M. The way forward in HCV treatment – finding the right path. Nature Rev. Drug Discov.6,991–1000 (2007).Crossref, Medline, CAS, Google Scholar19 De Clercq E. The design of drugs for HIV and HCV. Nature Rev. Drug Discov.6,1001–1018 (2007).▪ While HIV and hepatitis C virus are totally different in their genetic make-up, they share a number of similar targets for chemotherapeutic intervention.Crossref, Medline, CAS, Google Scholar20 De Clercq E. Antiviral drug discovery: ten more compounds, and ten more stories (part B). Med. Res. Rev.29,571–610 (2009).Crossref, Medline, Google Scholar21 De Clercq E. Antiviral agents active against influenza A viruses. Nature Rev. Drug Discov.5,1015–1025 (2006).Crossref, Medline, CAS, Google Scholar22 von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nature Rev. Drug Discov.6,967–974 (2007).Crossref, Medline, CAS, Google Scholar23 Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med.360,2605–2615 (2009).Crossref, Medline, Google Scholar24 Shinde V, Bridges CB, Uyeki TM et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–2009. N. Engl. J. Med.360,2616–2625 (2009).Crossref, Medline, CAS, Google Scholar25 Stevens AJ, Gahan ME, Mahalingam S, Keller PA. The medicinal chemistry of dengue fever. J. Med. Chem.52,7911–7926 (2009).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByFAITH – Fast Assembly Inhibitor Test for HIVVirology, Vol. 486Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and CoronavirusesJournal of Virology, Vol. 86, No. 21Synthesis of 2,3-dihydro-1,4-dithiinyl nucleosides via Pummerer-type glycosidationTetrahedron Letters, Vol. 51, No. 46Structure-based antivirals for emerging and neglected RNA viruses: an emerging field for medicinal chemistry in academiaRolf Hilgenfeld12 July 2010 | Future Medicinal Chemistry, Vol. 2, No. 7 Vol. 2, No. 7 Follow us on social media for the latest updates Metrics History Published online 12 July 2010 Published in print July 2010 Information© Future Science LtdAcknowledgementsThe author would like to thank Mrs Christiane Callebaut for her proficient editorial assistance.Financial & competing interests disclosureThe author is co-discoverer of tenofovir. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)